Abstract: A battery module for a vehicle, in particular for an aircraft, comprises a housing, a cell stack accommodated in the housing, an internal channel system for heat transfer fluid disposed in the housing, a fluid inlet connector and a fluid outlet connector connected to the internal channel system and adapted to being connected to an external thermal management system, wherein the fluid inlet connector and the fluid outlet connector are self-sealing connectors molded into the housing, preferably self-sealing and dripless connectors.

Abstract: The present invention relates to an aircraft, comprising a fuselage, at least one pair of wings and a battery system for providing power to electrical systems of the aircraft, wherein the battery system comprises at least one battery pack, each battery pack comprises a number of individual battery modules, which are directly or indirectly coupled to one another, and the at least one battery pack is disposed between an inner structural wall defining an interior space of the fuselage and an outer fairing wall of the fuselage. The fuselage is provided with a rack mounting mechanism comprising a number of mounting brackets, each for exchangeably mounting one of the battery modules to the aircraft, and each of the battery packs is a virtual battery pack, which is obtained by electrically connecting a predetermined number of the battery modules.

Abstract: A vapor cycle refrigeration system for an aircraft comprises a compressor, a condenser unit with a condenser radiator, a condenser fan and a condenser air duct configured to direct a stream of air generated by the condenser fan through the condenser radiator, an expansion device, an evaporator unit with an evaporator radiator, an evaporator fan and an evaporator air duct configured to direct a stream of air generated by the evaporator fan through the evaporator radiator, and a piping system connecting the compressor, the condenser radiator, the expansion device and the evaporator radiator in a closed circuit for a refrigerant, wherein each of the compressor, the condenser radiator, the condenser fan, the expansion device, the evaporator radiator, the evaporator fan and the piping system is fully supported directly or indirectly by at least one of the condenser air duct and the evaporator air duct such that the system is self-supporting.

Abstract: The invention relates to oxazolopyrimidine compounds of formula I, where A, R1 and R2 are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.

Abstract: The present invention relates to oxazolopyrimidine compounds of the formula I, in which A, R1, R2, R3 and X are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Abstract: Heterocyclic carboxylic acid derivatives comprising a 2,5-substituted oxazolopyrimidine ring as Edg-1 receptor agonists The present invention relates to oxazolopyrimidine compounds of the formula I, in which A, R1, R2, R3, X and Y are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Abstract: The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2, R3, R4, X and Y are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.

Abstract: The present invention relates to a lubricant composition Lubricant composition comprising at least one oil-soluble organic molybdenum compound, and at least one alkyl- or aryl-substituted ammonium tungstate, wherein the weight ratio of molybdenum to tungsten in the lubricant composition is at least 2.5:1, and the amount of molybdenum in the lubricant composition is at least 350 ppm based on the total weight of the lubricant composition. The compositions provide unexpected and substantially improved friction and abrasion properties over related compositions devoid of the invention. When using these lubricant compositions, for example in internal combustion engines, the engine power can be increased and the fuel consumption can be reduced.

Abstract: The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2 and R3 are defined as stated in the claims. The compounds of formula (I) are suitable, for example, for wound healing.

Abstract: The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2, R3, R4 and X are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.

Abstract: The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2, R3, R4, X and Y are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.

Abstract: The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2 and R3 are defined as stated in the claims. The compounds of formula (I) are suitable, for example, for wound healing.

Abstract: The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2, R3, R4 and X are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.

Abstract: The present invention relates to oxazolopyrimidine compounds of the formula I, in which A, R1, R2, R3 and X are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Abstract: Heterocyclic carboxylic acid derivatives comprising a 2,5-substituted oxazolopyrimidine ring as Edg-1 receptor agonists The present invention relates to oxazolopyrimidine compounds of the formula I, in which A, R1, R2, R3, X and Y are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Abstract: The invention relates to oxazolopyrimidine compounds of formula I, where A, R1 and R2 are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.

Abstract: The present invention relates to substituted phenothiazines with a double bond and physiologically acceptable salts thereof, and their use as a medicament.

Abstract: The present invention relates to substituted phenothiazines with a double bond and physiologically acceptable salts thereof, and their use as a medicament.

Abstract: The invention relates to compounds of the formula 1, wherein R1, R2, R3, R4, R5, R6, R7, A and B are as defined herein, the pharmaceutical compositions and the uses as pharmaceuticals.

Abstract: The present invention relates to a method for generating a focussed compound library containing ligand compounds being capable of binding to a pre-selected target. In particular, the invention relates to an integrated lead identification approach starting out from the three-dimensional structure of a selected target.